Patients with hematological tumors
Conditions
Interventions
Hematide group:Starting from the first day after transplantation, take 5mg/d Hematide on an empty stomach in the morning. For those who have been ineffective for 2 weeks, increase the dosage to 7.5mg/
rhTPO group:Starting from the first day after transplantation, rhTPO is injected subcutaneously at a dose of 15000 u/d until the platelet count rises to 50 × 109/L (maintained for 3 consecutive days w
Sponsors
Guangdong Provincial Hosipital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years old; 2. Patients with hematological tumors receiving allo HSCT treatment; 3. No use of rhTPO or non peptide TPO-RA prior to hematopoietic stem cell transplantation; 4. Those who agree to participate in this clinical study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Individuals who are allergic to research drugs and ingredients; 2. Patients with thromboembolic diseases that require treatment or those at high risk of developing thromboembolic diseases; 3. Merge severe organ dysfunction; 4. Patients currently participating in clinical trials of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet implantation rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The average time for platelet reconstruction; | — |
Countries
China
Contacts
Public ContactYuanbin Wu
Guangdong Provincial Hosipital of Chinese Medicine
Outcome results
None listed